key: cord-0759680-csknu6y3
authors: Le Joncour, Alexandre; Frere, Corinne; Martin-Toutain, Isabelle; Gougis, Paul; Ghillani-Dalbin, Pascale; Maalouf, Georgina; Vieira, Matheus; Marcelin, Anne-Geneviève; Salem, Joe-Elie; Allenbach, Yves; Saadoun, David; Benveniste, Olivier; Cacoub, Patrice
title: Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward
date: 2020-12-13
journal: Autoimmun Rev
DOI: 10.1016/j.autrev.2020.102729
sha: ab9acfeed90a13b14a5cd41287fcc48f50b7099d
doc_id: 759680
cord_uid: csknu6y3

nan

Rapidly after the first description of the new coronavirus disease (COVID-19) [1] , thrombotic events were increasingly reported as a common complication [2] [3] [4] [5] [6] [7] . Autopsy series further revealed deep venous thrombosis in up to 58% of severe COVID-19 patients in whom venous thromboembolism was not suspected before death [8] . In scarce studies reporting thromboembolic events in COVID-19 patients hospitalized in a medicine ward, the prevalence of thrombotic complications appeared lower, from 6.6 to 14% [6, 7, 9, 10] . Underlying mechanisms that may increase the risk of thrombotic events in COVID-19, called "COVID-19 coagulopathy", remain poorly understood. A role for antiphospholipid antibodies (aPL) has been suggested [10, 11] . In the present prospective single-center observational cohort study of COVID-19 patients admitted in the Internal Medicine Department of a tertiary care university hospital (Paris, France), we aimed to describe the prevalence of antiphospholipid markers in a consecutive series of non-ICU COVID-19-patients and to further assess whether there is a relationship between the presence of aPL and the occurrence of thrombotic events.

Included patients were older than 18 years with an initial requirement for hospitalization in a medical ward and a positive SARS-CoV-2 RT-PCR assay from nasal swabs. Patients were tested for the presence of aPL antibodies, i.e., aCL, aβ2GPI and for a subgroup, lupus anticoagulant. The ELISA QUANTALite™ (Inova Diagnostics, San Diego, CA) and the EliA β-2 Glycoprotein-1 (Phadia, Uppsala, Sweden) detection kits were used to detect IgG/IgM/IgA aCL and IgG/IgM/IgA aβ2GPI antibodies, respectively, with a limit of positivity fixed at 15 units/mL (99th percentile of a control population). Lupus anticoagulant (LA) testing was performed on a CS5100 analyzer according to the International Society on Thrombosis and Haemostasis guidelines. Thrombotic event was defined as a venous thrombosis or an arterial thrombotic event on admission or during follow up. Patients were followed-up until discharge, death, or up to 14 days. All patients benefited from the current standard of care for COVID-19 and received thromboprophylaxis according to current guidelines. Continuous variables are presented as median (interquartile range, IQR) and were compared using Wilcoxon'stest. Categorical variables are presented as count (percent) and were compared using Fisher's-test. All statistics were two-sided at a 5% significance level. Analyses were computed with IBM SPSS Statistics software (IBM Corp, Armonk, USA). The study followed the Strengthening Reporting of Observational Studies in Epidemiology for cohort studies. We received approval from the local ethiccommittee, and our study is registered as NCT04320017.

Between March 20 and April 23, 2020, a total of 104 patients were included. Main baseline features are presented in Table 1 . The median age was 71 years [59-81] and 60 (57.7%) patients were males. Patients had a past medical history of venous thrombosis, stroke and peripheral arterial disease in 15.4%, 10.6% and 8.7%, respectively. C-reactive protein (CRP) and D-dimer levels were both increased with median values of 69 mg/L [30-107] and 950 mg/L [480-1920], respectively. These general characteristics are in accordance with previously published series of COVID-19 patients [1] .

Eleven (10.6%) patients presented a thrombotic event on admission or during follow up, i.e., 9 acute pulmonary embolisms, 1 deep vein thrombosis and 1 aortic thrombus. The main differences in patient characteristics according to the presence of a thrombotic event are detailed in Table 1 . Patients with a thrombotic event had more frequently a past medical history of venous thrombosis (36.4% vs. 13.9%) and higher levels of neutrophil count (6460 vs. 4420/mm 3 3 . In a series of 184 critically ill COVID-19 patients, pulmonary embolism and deep vein thrombosis were found in 13.6% and 0.5%, respectively [2] . Venous thrombotic events have been associated with higher D-Dimer levels and prolonged aPPT [4] . Other studies reported pulmonary embolism in 6.6 to 10% in non-ICU patients [6, 7, 9, 10] .

In the present study, the presence of aCL was noted in 35/104 (33.7%) patients, mostly IgA aCL. Anti-β2-GPI were found in 9/104 (8.7%) patients. IgG, IgM and IgA aβ2-GPI were positive in 8 one positive aPL marker while double or triple antiphospholipid seropositivity was found in 11.1% and 1.9%, respectively. Then, we analyzed the results of aPL positivity according to the presence of thrombotic events. Anticardiolipin antibodies were more frequently found in patients with thrombotic events. The only aCL isotypes significantly associated with thrombotic events were IgG and IgM aCL (p = 0.037 and p < 0.001, respectively). IgA aβ2-GPI were more frequently found in patients with thrombotic events Overall, almost half of non-ICU COVID-19 patients had at least one aPL, mainly aCL whereas aβ2-GPI were more rarely found (<10%). Viral-induced aCL are rarely associated with aβ2-GPI, often transient and are not correlated with thrombosis risk [12] . One limitation of this study is that we could not assess if these aPL were persistent are not. In a COVID-19 case series of 216 patients, lupus anticoagulant was found in 31 out of 35 of those with a prolonged aPPT, from which only two had suspected or confirmed venous thrombotic events [13] . Moreover, a series of 150 critically ill patients showed lupus anticoagulant in 50 out of 57 patients tested [3] .

In conclusion, antiphospholipid antibodies, even weak and/or transient, are common in COVID-19 patients hospitalized in a medicine ward. In this prospective cohort, 64% of patients with a thrombotic event were found to have aPL antibodies. Only the presence of aCL and aβ2-GPI antibodies were significantly associated with the occurrence of thrombotic events. Although our results suggest that antiphospholipid antibodies are common in non severe COVID-19, their relationship with thrombosis and COVID-19 associated coagulopathy will necessitate more dedicated studies.

None.

None.

A novel coronavirus from patients with pneumonia in China

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Acute pulmonary embolism associated with COVID-19 pneumonia detected by pulmonary CT angiography

Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels

Autopsy findings and venous thromboembolism in patients with COVID-19

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Lupus anticoagulant is frequent in patients with Covid-19

Antiphospholipid antibodies, antiphospholipid syndrome and infections

Lupus anticoagulant and abnormal coagulation tests in patients with covid-19

We thank Besma Abdi, Cathia Soulie and Elisa Teyssou for their technical assistance.